Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LK101 / Likang Life Sci
NCT05886439: LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer	Recruiting	1	40	RoW	LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab, Durvalumab	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Advanced Lung Carcinoma	07/25	12/26
NCT06054932: Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors	Recruiting	1	18	RoW	LK101 injection	Beijing Likang Life Science and Tech Co., Ltd.	Advanced Solid Tumor	12/25	03/26